DGAP-Media / 2020-01-08 / 11:08
*Aladdin Healthcare Technologies SE release a SAAS prototype for Early
Diagnosis of Alzheimer's Disease based on blood test results*
(BERLIN, Germany and LONDON, England) 08 January 2020 Aladdin Healthcare
Technologies SE ("Aladdin"), a leading developer of next generation
breakthroughs in age-related disease accelerated by the integration of
leading science and A.I today announced we have released our, SAAS (software
as a service) based, online rapid analysis report prototype for early
diagnosis for Alzheimer's Disease, based on blood test results.
Ageing is a global megatrend, as the world continues to age rapidly,
age-related diseases have become a significant healthcare burden for all
governments. Alzheimer's Disease is one of the most crippling age-related
diseases, there are more than 50 million dementia patients globally which
created a global economic burden of more than $1 trillion in 2018.
Currently there is no affordable and accurate early stage universal testing
for Alzheimer's Disease. All methods are either invasive and painful,
expensive or inaccurate.
Our A.I diagnosis is based on a non-invasive blood test, which can provide
instant diagnosis for health screening of multiple age-related diseases. We
have achieved 85% accuracy for diagnosing Alzheimer's Disease through our
A.I model based on blood test results. These diagnostics will now be
validated through our extensive and industry leading hospital network. This
is a catalyst for our second phase, which potentially will make further
significant gains and breakthroughs towards a seamless blood test setting a
new gold standard for Alzheimer's Disease early diagnosis.
Evidence shows that early diagnosis and intervention of key diseases can not
only help postpone or ameliorate symptoms but also lead to enhanced
longevity. On top of this, early diagnosis is also a significant component
for pharmaceutical companies to gain access to a key demographic for
clinical trials that can expedite drug discovery.
The CEO, Wade Menpes-Smith states "This is clearly a significant
breakthrough moment for Aladdin and fundamentally transforms the outlook for
the company. I'm satisfied we have met the first milestone for this product,
and we look forward to both validating our product with our globally
respected partnership network and further improving the accuracy."
Wade Menpes-Smith (Chairman)
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin
Healthcare Technologies Ltd.) is a leading developer of AI healthcare
diagnostics and drug discovery applications that can accelerate both early
stage disease diagnosis and the end-to-end drug discovery process. Aladdin
targets aged related disease including a significant focus on Alzheimer's
disease. Aladdin accomplishes this by collaborating with numerous partners
within the global healthcare ecosystem to confidentially and securely gather
targeted data including, genome, tabular, MRI, PET, cognition and other
lifestyle data. These datasets are then analysed by our award-winning AI
team and used to develop proprietary AI tools that can assist healthcare
professionals to more accurately and efficiently diagnose aged related
diseases. This new diagnostic process will save significant time and costs
for healthcare professionals. Additionally, our AI drug discovery platform
will be used to by pharmaceutical Companies to speed up drug development,
clinical trials and predict outcomes more accurately.
End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
2020-01-08 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 948917
End of News DGAP Media
948917 2020-01-08
(END) Dow Jones Newswires
January 08, 2020 05:08 ET (10:08 GMT)
© 2020 Dow Jones News
